Vanda wins EU orphan status for imsidolimab
Share
Vanda Pharmaceuticals (NASDAQ:VNDA) announced that the European Commission granted orphan designation to imsidolimab for the treatment of generalized pustular psoriasis, following a positive opinion from the EMA Committee for Orphan Medicinal Products.
